Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 435

1.

The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.

Bliven EE, Podewils LJ.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1054-60. Review.

PMID:
19723392
[PubMed - indexed for MEDLINE]
2.

Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 5;59(8):224-9.

PMID:
20203555
[PubMed - indexed for MEDLINE]
Free Article
3.

[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].

Kaneko Y, Nagayama N, Kawabe Y, Shimada M, Suzuki J, Kunogi M, Matsui Y, Kawashima M, Suzuki J, Ariga H, Oshima N, Masuda K, Matsui H, Nagai H, Tamura A, Akagawa S, Toyoda E, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2008 Jan;83(1):13-9. Japanese.

PMID:
18283910
[PubMed - indexed for MEDLINE]
4.

Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.

Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS.

Clin Exp Rheumatol. 2000 May-Jun;18(3):363-8.

PMID:
10895374
[PubMed - indexed for MEDLINE]
5.

Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.

Kunst H, Khan KS.

Int J Tuberc Lung Dis. 2010 Nov;14(11):1374-81. Review.

PMID:
20937175
[PubMed - indexed for MEDLINE]
6.

Isoniazid hepatotoxicity in renal transplant recipients.

Antony SJ, Ynares C, Dummer JS.

Clin Transplant. 1997 Feb;11(1):34-7.

PMID:
9067692
[PubMed - indexed for MEDLINE]
7.

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ; Terry Beirn Community Programs for Clinical Research on AIDS; Adult AIDS Clinical Trials Group; Centers for Disease Control and Prevention.

Clin Infect Dis. 2004 Aug 15;39(4):561-5. Epub 2004 Jul 30.

PMID:
15356822
[PubMed - indexed for MEDLINE]
Free Article
8.

Treatment of latent tuberculosis infection: An update.

Lobue P, Menzies D.

Respirology. 2010 May;15(4):603-22. doi: 10.1111/j.1440-1843.2010.01751.x. Epub 2010 Apr 7. Review.

PMID:
20409026
[PubMed - indexed for MEDLINE]
9.

Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.

Fresard I, Bridevaux PO, Rochat T, Janssens JP.

Swiss Med Wkly. 2011 Aug 15;141:w13240. doi: 10.4414/smw.2011.13240.

PMID:
21842452
[PubMed - indexed for MEDLINE]
Free Article
10.

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.

Fountain FF, Tolley E, Chrisman CR, Self TH.

Chest. 2005 Jul;128(1):116-23.

PMID:
16002924
[PubMed - indexed for MEDLINE]
11.

Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data.

Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ.

Liver Transpl. 2009 Aug;15(8):894-906. doi: 10.1002/lt.21709. Review.

PMID:
19642133
[PubMed - indexed for MEDLINE]
Free Article
12.

Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection.

Aziz H, Shubair M, Debari VA, Ismail M, Khan MA.

Curr Med Res Opin. 2006 Jan;22(1):217-21.

PMID:
16393447
[PubMed - indexed for MEDLINE]
13.

Isoniazid hepatotoxicity among drug users: the role of hepatitis C.

Fernández-Villar A, Sopeña B, Vázquez R, Ulloa F, Fluiters E, Mosteiro M, Martínez-Vázquez C, Piñeiro L.

Clin Infect Dis. 2003 Feb 1;36(3):293-8. Epub 2003 Jan 15.

PMID:
12539070
[PubMed - indexed for MEDLINE]
Free Article
14.

Isoniazid-related hepatitis.

Vasudeva R, Woods B.

Dig Dis. 1997 Nov-Dec;15(6):357-67. Review.

PMID:
9439900
[PubMed - indexed for MEDLINE]
15.

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J, Hochstrasser D.

Eur J Clin Pharmacol. 2006 Jun;62(6):423-9. Epub 2006 Apr 27.

PMID:
16770646
[PubMed - indexed for MEDLINE]
16.

[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].

Camacho A, Pérez-Camacho I, Rivero A, Natera C, García-Lázaro M, Castón JJ, Gallo M, Kindelán JM, Torre-Cisneros J.

Enferm Infecc Microbiol Clin. 2010 Apr;28(4):239-44. doi: 10.1016/j.eimc.2009.04.003. Epub 2009 Aug 3. Spanish.

PMID:
19647900
[PubMed - indexed for MEDLINE]
17.

Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.

Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, Guleria S, Mehta SN.

Transpl Infect Dis. 2005 Sep-Dec;7(3-4):99-108.

PMID:
16390397
[PubMed - indexed for MEDLINE]
18.

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.

Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ.

Chest. 2005 Apr;127(4):1304-11.

PMID:
15821209
[PubMed - indexed for MEDLINE]
19.

Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity.

Fernández-Villar A, Sopeña B, García J, Gimena B, Ulloa F, Botana M, Martínez-Vázquez C.

Infection. 2007 Jun;35(4):295-7. Epub 2007 Jul 23. No abstract available.

PMID:
17646919
[PubMed - indexed for MEDLINE]
20.

Is isoniazid safe for liver transplant candidates with latent tuberculosis?

Stucchi RS, Boin IF, Angerami RN, Zanaga L, Ataide EC, Udo EY.

Transplant Proc. 2012 Oct;44(8):2406-10. doi: 10.1016/j.transproceed.2012.07.035.

PMID:
23026607
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk